ClinicalTrials.gg
RecruitingNCT06179459Updated Jul 9, 2026

Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections

An observational study in Acute Pancreatitis, Pancreatic Pseudocyst and Pancreatic Necrosis, sponsored by Orlando Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Primary conditionPancreatitis, Acute NecrotizingRegistry: PancreatitisReclassifiedWhy we changed it
Registry
Pancreatitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pancreatitis, Acute Necrotizing
Why
  1. The study's listed conditions name Pancreatitis, Acute Necrotizing, a narrower term within Pancreatitis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Orlando Health, Inc. · Observational

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
110
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Pancreatitis, Acute Necrotizing with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Pancreatitis, Acute Necrotizing · United States.

Started
2021
with 1 other
Observational
7 of 20
1 open now
Registered
17th of 20
by date
Lead sponsor
3 of 20
Orlando Health, Inc.

Among the 20 studies in Pancreatitis, Acute Necrotizing with a site in United States, this one is one of 2 that started in 2021, is one of 7 observational ones, and was the 17th registered.

Pancreatitis, Acute Necrotizing

75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.

Browse Pancreatitis, Acute Necrotizing studies →

Open to participants now

3 of the 20 studies in Pancreatitis, Acute Necrotizing with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Pancreatitis, Acute Necrotizing studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Pancreatitis, Acute Necrotizing with a site in United States, or all of them as a file.
02

Study summary

Acute pancreatitis is one of the most common gastrointestinal disorders requiring hospitalization worldwide. Pancreatic fluid collections can occur as a consequence of acute and chronic pancreatitis and can result in significant morbidity and mortality, including significant abdominal pain, gastric outlet obstruction, biliary obstruction, organ failure, persistent unwellness, infection and sepsis.

Symptomatic pancreatic fluid collections require treatment, and endoscopic drainage is considered standard of care. The aim of this study is to evaluate the treatment outcomes in patients undergoing standard of care, endoscopic treatment of pancreatic fluid collections.

Read the detailed description

Acute pancreatitis has an annual incidence of 13-45 cases per 100,000 persons and is one of the most common gastrointestinal disorders requiring hospitalization worldwide. It leads to over a quarter of a million hospital admissions annually in the United States, and inpatient costs exceeding 2.5 billion US dollars. Pancreatic fluid collections can occur as a consequence of acute and chronic pancreatitis and can result in significant morbidity and mortality, including significant abdominal pain, gastric outlet obstruction, biliary obstruction, organ failure, persistent unwellness, infection and sepsis.

Symptomatic pancreatic fluid collections require treatment, and endoscopic drainage is considered standard of care. Endoscopic treatment involves the drainage of the fluid collection into the stomach or duodenum by placement of metal or plastic stents. If clinically indicated, endoscopic necrosectomy is also performed, which is the removal of devitalized pancreatic tissue using the endoscope. Currently the treatment success rate of endoscopic treatment of pancreatic fluid collections exceeds 90%.

The aim of this study is to evaluate the treatment outcomes in patients undergoing standard of care, endoscopic treatment of pancreatic fluid collections.

03

Conditions studied

  • Acute Pancreatitis
  • Pancreatic Pseudocyst
  • Pancreatic Necrosis

Browse trials for

04

In context

Pancreatitis, Acute Necrotizing Reclassified

75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.

This study's planned enrollment of 110 is close to the median of 101 across 26 observational studies indexed under Pancreatitis, Acute Necrotizing.

Browse Pancreatitis, Acute Necrotizing studies →

Lead sponsor

Orlando Health, Inc. is the lead sponsor of 28 studies on the registry; 10 are open to participants now.

Compared within Pancreatitis, Acute Necrotizing, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pancreatitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with pancreatic fluid collections

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • All patients undergoing endoscopic treatment of pancreatic fluid collections

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Patients who did not receive endoscopic treatment of pancreatic fluid collections
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
110 participants (estimated)
Patient registry
No

Interventions

  • ProcedureEndoscopic management of pancreatic fluid collections

    Patients with pancreatic fluid collections will be undergoing EUS-guided drainage and/or endoscopic necrosectomy

07

What researchers measure

Primary outcomes

  1. Treatment outcomes in patients undergoing endoscopic treatment of pancreatic fluid collections according to timing of treatment.

    Treatment outcomes in patients undergoing endoscopic treatment of pancreatic fluid collections is assessed as a composite measure consisting of 1) adverse events or 2) need for hospital admission due to underlying disease or procedure-related adverse events, in patients undergoing endoscopic treatment of pancreatic fluid collections, according to timing of treatment.

    Time frame: 6 months

Secondary outcomes

  1. Treatment success

    Rate of treatment success, defined as the resolution of pancreatic fluid collection on CT scan in association with clinical resolution of symptoms at 6-months from index intervention.

    Time frame: 6 months

  2. Number and type of interventions performed

    Number of interventions performed to achieve treatment success

    Time frame: 6 months

  3. Need for surgical intervention

    Need for any surgical intervention in patients undergoing endoscopic therapy for pancreatic fluid collections.

    Time frame: 6 months

  4. Technical success of endoscopic interventions in pancreatic fluid collections.

    Technical success of endoscopic interventions in pancreatic fluid collections.

    Time frame: 6 months

  5. Inflammatory response and organ failure in patients undergoing endoscopic therapy for pancreatic fluid collections.

    Rate of inflammatory response and organ failure in patients undergoing endoscopic therapy for pancreatic fluid collections.

    Time frame: 6 months

  6. Disease-related adverse events

    Rate of disease-related adverse events

    Time frame: 6 monthts

  7. Procedure-related adverse events

    Procedure-related adverse events in patients undergoing endoscopic management of pancreatic fluid collection

    Time frame: 6 months

  8. Timing of intervention

    Intervention at 4 weeks since onset of pancreatitis (traditional approach) versus intervention when the area of necrosis is contained or only partially encapsulated.

    Time frame: 6 months

  9. Hounsfield units of the pancreatic fluid collection

    Impact of hounsfield units in the necrotic collection on endoscopic intervention

    Time frame: 6 months

  10. Impact of partial versus full encapsulation of pancreatic fluid collections

    Impact of partial versus full encapsulation of pancreatic fluid collections on endoscopic intervention

    Time frame: 6 months

  11. Incidence of disconnected pancreatic duct syndrome and sequelae of disconnected pancreatic duct syndrome

    Incidence of disconnected pancreatic duct syndrome and sequelae of disconnected pancreatic duct syndrome

    Time frame: 6 months

  12. Hospital admission

    Rate of hospital readmissions due to disease-related or procedure-related events in patients undergoing endoscopic therapy for pancreatic fluid collections.

    Time frame: 6 months

  13. Disease recurrence

    Rate of disease recurrence in patients undergoing endoscopic management of pancreatic fluid collections

    Time frame: 6 months

  14. Diabetes

    Rate of diabetes

    Time frame: 6 months

  15. Exocrine pancreatic insufficiency

    Rate of exocrine pancreatic insufficiency

    Time frame: 6 months

  16. Treatment costs

    Treatment costs from admission until hospital discharge

    Time frame: 6 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2021 (actual). Primary completion is estimated for Dec 2027, 79 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Dec 21, 2023
StartActual
May 1, 2021
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06179459
Lead sponsor
Orlando Health, Inc.
Responsible party
Sponsor
First posted
Dec 21, 2023
Start date
May 1, 2021
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 9, 2026

Study contacts

Ji Young Bang
Contact
jiyoung.bang@orlandohealth.com
321-841-2431
Barbara J Broome
Contact
barbara.broome@orlandohealth.com
321-841-4356
Ji Young Bang, MD MPH
principal investigator · Orlando Health, Digestive Health Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion